A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib - Concepedia

Concepedia

Publication | Open Access

A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib

DOI Full Paper Access

54

Citations

27

References

2016

Year

Helena A. Yu, Leslie Perez, Qing Chang, Sizhi Paul Gao, Mark G. Kris, Gregory J. Riely, Jacqueline Bromberg

Journal of Thoracic Oncology

Phase 1/2OncologyAcquired ResistanceMedicinePathologyCancer TreatmentCancer GeneticsPharmacologyRadiation OncologyLung CancerMolecular Oncology

References

	Year	Citations

Page 1

Page 1